Monitor the conversion premium and stock price relative to the conversion price ($334.27). If LGND trades above the conversion price, volatility and volume may increase due to convertible arbitrage activity. Also watch for updates on the XOMA acquisition closing and integration.
LGND drugs
LGND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $303.59entry
- T+1 · 5mo ago +3.44%α +1.79% · $314.04
- T+5 · 4mo ago +5.26%α +3.09% · $319.55
- T+20 · 4mo ago −0.47%α −1.74% · $302.15
- T+60 · 8w ago −4.45%α −10.56% · $290.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes due 2031, with an initial conversion price of approximately $334.27 per share, and concurrently entered into a bond hedge (capped call) and warrant transactions to manage dilution. The proceeds are intended to help fund the pending acquisition of XOMA Royalty Corporation. The capital raise introduces dilution risk but is partially offset by the bond hedge, while the warrants add additional potential dilution if the stock exceeds the strike price.
Key Financial Metrics
Key Facts
- Issued $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2031
- Initial conversion rate of 2.9916 shares per $1,000 principal, equating to an initial conversion price of ~$334.27 per share
- Notes are zero-coupon and mature on September 15, 2031
- Bond hedge (capped call) and warrant transactions entered into with dealers to manage dilution and provide additional upside exposure
- Proceeds likely used to fund the acquisition of XOMA Royalty Corporation (announced April 27, 2026)
Financial Impact
Up to 2.09 million shares of dilution upon full conversion of notes, plus further dilution from warrants if stock exceeds warrant strike; offset by bond hedge that reduces dilution at higher stock prices.
Risk Factors
- Dilution from note conversion and warrants could pressure EPS
- Increased leverage from $700M debt obligation
- Potential overhang from the convertible offering and related hedging activities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-282990 |
| Document: d167360dex101.htm | 0001193125-26-282990 |
| Document: d167360dex102.htm | 0001193125-26-282990 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers